Arcturus/CSL COVID-19 Vaccine Shows Enhanced, Durable Immune Response Compared to Comirnaty
核心洞察
Arcturus Therapeutics (搜索) and CSL (搜索)'s self-amplifying mRNA vaccine, ARCT-154, demonstrates superior immune responses compared to BioNTech/Pfizer (搜索)'s Comirnaty vaccine after 12 months.
The Phase III trial in Japan showed ARCT-154 elicited significantly more neutralizing antibodies against various SARS-CoV-2 (搜索) strains than Comirnaty at the 12-month mark.
Arcturus' self-amplifying mRNA technology allows for quick and long-lasting antigen expression, potentially providing more durable protection against COVID-19 (搜索) with lower doses.
A new study comparing Arcturus Therapeutics (搜索)' self-replicating mRNA-based COVID-19 (搜索) vaccine, ARCT-154, developed in collaboration with CSL (搜索), to BioNTech/Pfizer (搜索)’s Comirnaty vaccine, reveals a more robust and durable immune response 12 months post-vaccination. The findings, presented at the OPTIONS XII for the Control of Influenza conference, highlight the potential of Arcturus' self-amplifying mRNA technology to offer enhanced protection against SARS-CoV-2 (搜索).
Superior Antibody Response
The Phase III trial, conducted in Japan, involved 930 participants who had previously received at least three doses of an mRNA COVID-19 (搜索) vaccine. Participants were randomized to receive a booster vaccination with either ARCT-154 or Comirnaty. The results indicated that individuals who received ARCT-154 exhibited significantly higher levels of neutralizing antibodies against various SARS-CoV-2 (搜索) strains compared to those who received Comirnaty at the 12-month follow-up.
Self-Amplifying mRNA Technology
Arcturus' self-amplifying technology facilitates rapid and prolonged antigen expression within target cells, which is designed to stimulate a stronger immune response to potential pathogens like SARS-CoV-2 (搜索). This approach may offer a more effective and longer-lasting defense against COVID-19 (搜索), even at lower doses compared to conventional mRNA vaccines.
Expert Commentary
"The 12-month results from the ARCT-154 study continue to establish the durability of immune response from this self-amplifying mRNA vaccine and reinforce the ability of this vaccine to provide protection against COVID-19 (搜索) at lower doses compared to conventional mRNA vaccines," said Jonathan Edelman, MD, senior vice president, Vaccines Innovation Unit, at CSL (搜索).
Bivalent Vaccine Development
Arcturus and CSL (搜索) are also actively developing a bivalent version of their vaccine, ARCT-2301, to target emerging strains of the virus. Preliminary research suggests that ARCT-2301 demonstrates superior immunogenicity compared to the bivalent version of Comirnaty.
Addressing the Need for Durable Protection
"The recent surge in COVID-19 (搜索) infections and the emerging new variants illustrate the critical need for vaccines that provide a longer duration of protection compared to conventional mRNA vaccines," said Igor Smolenov, chief development officer of Arcturus Therapeutics (搜索). "These compelling new studies reaffirm that these self-amplifying-mRNA vaccines have the potential to offer potent protection against COVID-19."